Genotype-phenotype correlation for nucleotide substitutions in the IgII-IgIII linker of FGFR2.

Dominantly acting, allelic mutations of the fibroblast growth factor receptor 2 (FGFR2) gene have been described in five craniosynostosis syndromes. In Apert syndrome, characterised by syndactyly of the hands and feet, recurrent mutations of a serine-proline dipeptide (either Ser252Trp or Pro253Arg) in the linker between the IgII and IgIII extracellular immunoglobulin-like domains, have been documented in more than 160 unrelated individuals. We have identified three novel mutations of this dipeptide, associated with distinct phenotypes. A C-->T mutation that predicts a Ser252Leu substitution, ascertained in a boy with mild Crouzon syndrome (craniosynostosis with normal limbs) is also present in three clinically normal members of his family. A CG-->TT mutation that predicts a Ser252Phe substitution results in a phenotype consistent with Apert syndrome. Finally, a CGC-->TCT mutation that predicts a double amino acid substitution (Ser252Phe and Pro253Ser) causes a Pfeiffer syndrome variant with mild craniosynostosis, broad thumbs and big toes, fixed extension of several digits, and only minimal cutaneous syndactyly. The observation that the Ser252Phe mutation causes Apert syndrome, whereas the other single or double substitutions are associated with milder or normal phenotypes, highlights the exquisitely specific molecular pathogenesis of the limb and craniofacial abnormalities associated with Apert syndrome. Ser252Phe is the first noncanonical mutation to be identified in this disorder, its rarity being explained by the requirement for two residues of the serine codon to be mutated. The description of independent, complex nucleotide substitutions involving identical nucleotides is unprecedented, and we speculate that this may result from functional selection of FGFR mutations in sperm.

[1]  E. Zackai,et al.  Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes , 1996, Nature Genetics.

[2]  D. Cooper,et al.  Human Gene Mutation Database , 1996, Human Genetics.

[3]  S. Sommer,et al.  Absence of somatic mosaicism in 17 families with hemophilia B: an analysis with a sensitivity 10- to 1000-fold greater than that of sequencing gels , 1996, Human Genetics.

[4]  D. Donoghue,et al.  Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II , 1996, Molecular and cellular biology.

[5]  M. Bamshad,et al.  Fibroblast growth factor receptor 2 mutations in Beare–Stevenson cutis gyrata syndrome , 1996, Nature Genetics.

[6]  A. N. Meyer,et al.  Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  D. Ornitz,et al.  Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia , 1996, Nature Genetics.

[8]  Steven A. Wall,et al.  Exclusive paternal origin of new mutations in Apert syndrome , 1996, Nature Genetics.

[9]  J. Hurst,et al.  Differential effects of FGFR2 mutations on syndactyly and cleft palate in Apert syndrome. , 1996, American journal of human genetics.

[10]  A. Munnich,et al.  Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). , 1996, Human molecular genetics.

[11]  A. Wilkie,et al.  Craniosynostosis: novel insights into pathogenesis and treatment , 1996, Current opinion in neurology.

[12]  E. Jabs,et al.  FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. , 1996, American journal of human genetics.

[13]  D. Donoghue,et al.  Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. , 1996, The EMBO journal.

[14]  I. Munro,et al.  Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans , 1995, Nature Genetics.

[15]  R. Friesel,et al.  Constitutive Activation of Fibroblast Growth Factor Receptor-2 by a Point Mutation Associated with Crouzon Syndrome (*) , 1995, The Journal of Biological Chemistry.

[16]  E. Jabs,et al.  Mutations in fibroblast growth factor receptors: phenotypic consequences during eukaryotic development. , 1995, American journal of human genetics.

[17]  M. Muenke,et al.  Fibroblast-growth-factor receptor mutations in human skeletal disorders. , 1995, Trends in genetics : TIG.

[18]  E. Jabs,et al.  Analysis of phenotypic features and FGFR2 mutations in Apert syndrome. , 1995, American journal of human genetics.

[19]  J. Heath,et al.  Functions of fibroblast growth factors and their receptors , 1995, Current Biology.

[20]  S. Sommer.  Recent human germ-line mutation: inferences from patients with hemophilia B. , 1995, Trends in genetics : TIG.

[21]  E. Zackai,et al.  Mutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndrome. , 1995, Human molecular genetics.

[22]  W. Reardon,et al.  Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome , 1995, Nature Genetics.

[23]  W. Reardon,et al.  Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes , 1995, Nature Genetics.

[24]  W. Reardon,et al.  A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome , 1994, Nature Genetics.

[25]  M. Eccles,et al.  Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2 , 1994, Nature Genetics.

[26]  M. Nelson,et al.  Effect of site-specific modification on restriction endonucleases and DNA modification methyltransferases. , 1994, Nucleic acids research.

[27]  S. Clark,et al.  High sensitivity mapping of methylated cytosines. , 1994, Nucleic acids research.

[28]  J. Lavergne,et al.  Human Gene Mutation , 1994 .

[29]  S. Aaronson,et al.  High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Givol,et al.  Multiple structural elements determine ligand binding of fibroblast growth factor receptors. Evidence that both Ig domain 2 and 3 define receptor specificity. , 1993, The Journal of biological chemistry.

[31]  J. Xu,et al.  Substitution of putative half-cystine residues in heparin-binding fibroblast growth factor receptors. Loss of binding activity in both two and three loop isoforms. , 1992, The Journal of biological chemistry.

[32]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Jaye,et al.  Cloning and expression of two distinct high‐affinity receptors cross‐reacting with acidic and basic fibroblast growth factors. , 1990, The EMBO journal.

[34]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[35]  H. J. Evans,et al.  Advances in Cancer Research , 1985, British Journal of Cancer.

[36]  R. Grantham.  Amino Acid Difference Formula to Help Explain Protein Evolution , 1974, Science.

[37]  E. Hovig,et al.  CDKN2A (p16INK4A) somatic and germline mutations , 1996, Human mutation.

[38]  D. Ricke,et al.  Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses , 1996, Human mutation.

[39]  Dirk,et al.  Effect of fibroblast growth factor-2 on Sertoli cells and gonocytes in coculture during the perinatal period. , 1996, Endocrinology.

[40]  D. Johnson,et al.  Structural and functional diversity in the FGF receptor multigene family. , 1993, Advances in cancer research.